Table 2.
Characteristics of the study participants according to treatment arm
| Baseline characteristics | Goadsby et al., 2020 [23] | Ailani et al., 2021 [24] | ||||||
|---|---|---|---|---|---|---|---|---|
| Placebo (n = 186) | Atogepant 10 mg (n = 93) | Atogepant 30 mg (n = 183) | Atogepant 60 mg (n = 186) | Placebo (n = 222) | Atogepant 10 mg (n = 221) | Atogepant 30 mg (n = 228) | Atogepant 60 mg (n = 231) | |
| Age, years | 40.5 (11.7) | 39.4 (12.4) | 41.0 (13.6) | 40.4 (11.7) | 40.3 (12.8) | 41.4 (12.0) | 42.1 (11.7) | 42.5 (12.4) |
| Female sex | 154 (82.8%) | 82 (88.2%) | 166 (90.7%) | 156 (83.9%) | 198 (89.2%) | 200 (90.5%) | 204 (89.5%) | 199 (86.1%) |
| Ethnic origin | ||||||||
| White | 137 (73.7%) | 69 (74.2%) | 145 (79.2%) | 133 (71.5%) | 194 (87.4%) | 181 (81.9%) | 185 (81.1%) | 192 (83.1%) |
| Black | 45 (24.2%) | 20 (21.5%) | 29 (15.8%) | 44 (23.7%) | 24 (10.8%) | 34 (15.4%) | 38 (16.7%) | 28 (12.1%) |
| Other | 4 (2.1%) | 4 (4.3%) | 9 (5.0%) | 9 (4.8%) | 4 (1.8%) | 6 (2.7%) | 5 (2.2%) | 11 (4.8%) |
| Body mass index, kg/m2 | 30.4 (7.6) | 29.9 (7.3) | 30.0 (7.1) | 30.0 (7.8) | 30.8 (8.7) | 30.3 (7.6) | 31.1 (7.6) | 29.9 (7.3) |
| Current use of acute medications | 181 (97.3%) | 90 (96.8%) | 181 (98.9%) | 179 (96.2%) | 896 (99.3%) | |||
| Monthly migraine days | 7.7 (2.5) | 7.7 (2.6) | 7.2 (2.5) | 7.3 (2.4) | 7.3 (2.4) | |||
| Monthly headache days | 8.9 (2.7) | 9.5 (2.8) | 9.3 (2.7) | 9.2 (2.7) | 9.1 (2.7) | |||
| Monthly acute medication use days | 6.5 (3.2) | 6.5 (3.1)a | 6.6 (3.0)a | 6.7 (3.0)a | 6.9 (3.2)a | |||
Data are means (SD) or n (%)
SD standard deviation
aModified intention-to-treat population